Quarterly report pursuant to Section 13 or 15(d)

Other Intangible Assets

v3.19.1
Other Intangible Assets
 3 Months Ended
Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Other Intangible Assets
4. OTHER INTANGIBLE ASSETS

 

The net carrying value of the identifiable intangible assets as of March 31, 2019 and December 31, 2018 are as follows:

 

          As of
March 31, 2019 		    As of
December 31, 2018 		 
          (unaudited)        
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
Diagnostic assets:                        
Asuragen acquisition:                        
Thyroid     9     $ 8,519     $ 8,519  
RedPath acquisition:                        
Pancreas test     7       16,141       16,141  
Barrett’s test     9       18,351       18,351  
Total           $ 43,011     $ 43,011  
Diagnostic lab:                        
CLIA Lab     2.3     $ 609     $ 609  
                         
Accumulated Amortization           $ (14,580 )   $ (10,515 )
                         
Net Carrying Value           $ 29,040     $ 33,105  

 

Amortization expense was approximately $0.8 million for the three-month periods ended March 31, 2019 and 2018, respectively. Amortization of our diagnostic assets begins upon launch of the product. Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:

 

2019     2020     2021     2022     2023  
$ 3,252     $ 4,272     $ 4,908     $ 2,987     $ 2,987